Quipt Home Medical (QIPT)
(Delayed Data from NSDQ)
$3.04 USD
+0.10 (3.40%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $3.03 -0.01 (-0.33%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.04 USD
+0.10 (3.40%)
Updated Oct 16, 2024 04:00 PM ET
After-Market: $3.03 -0.01 (-0.33%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
Zacks News
Quipt Home Medical Corp. (QIPT) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Quipt Home Medical (QIPT) delivered earnings and revenue surprises of -500% and 1.64%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Canopy Growth (CGC) delivered earnings and revenue surprises of -19.35% and 6.61%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Misses Q1 Earnings Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of -0.97% and 0.09%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Quipt Home Medical Corp. (QIPT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quipt Home Medical (QIPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prestige Consumer Healthcare (PBH) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of -10.53% and 3.46%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Phibro (PAHC) Moves 31.8% Higher: Will This Strength Last?
by Zacks Equity Research
Phibro (PAHC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Quipt Home Medical Corp. (QIPT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 66.67% and 3.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Agios Pharmaceuticals (AGIO) Q4 Earnings Expected to Decline
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quipt Home Medical Corp. (QIPT) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 100% Upside in Quipt Home Medical Corp. (QIPT): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 100% upside potential for Quipt Home Medical Corp. (QIPT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Quipt Home Medical Corp. (QIPT) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of -250% and 1.69%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Asensus Surgical (ASXC) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Asensus Surgical (ASXC) delivered earnings and revenue surprises of -28.57% and 18.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Quanterix Corporation (QTRX) Soars 33.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Envista (NVST) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Envista (NVST) delivered earnings and revenue surprises of -7.32% and 0.59%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Quipt Home Medical Corp. (QIPT) to Report Q1 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Quipt Home Medical Corp. (QIPT) Beats Q4 Earnings Estimates
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 25% and 1.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Quipt Home Medical Corp. (QIPT) Reports Break-Even Earnings for Q3
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of -100% and 0.65%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Veru Inc. (VERU) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Veru Inc. (VERU) delivered earnings and revenue surprises of -55.56% and 42.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Haemonetics (HAE) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Haemonetics (HAE) delivered earnings and revenue surprises of 9.43% and 4.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Cerus (CERS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cerus (CERS) delivered earnings and revenue surprises of 16.67% and 2.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Quanterix Corporation (QTRX): Can Its 5.1% Jump Turn into More Strength?
by Zacks Equity Research
Quanterix Corporation (QTRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Quipt Home Medical Corp. (QIPT) Tops Q2 Earnings Estimates
by Zacks Equity Research
Quipt Home Medical Corp. (QIPT) delivered earnings and revenue surprises of 366.67% and 4.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Poseida Therapeutics, Inc. (PSTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Poseida Therapeutics, Inc. (PSTX) delivered earnings and revenue surprises of -60.34% and 42.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Quipt (QIPT) Ahead of Earnings?
by Zacks Equity Research
Quipt (QIPT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
OraSure Technologies (OSUR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of -100% and 4.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?